{
    "clinical_study": {
        "@rank": "41939", 
        "arm_group": [
            {
                "arm_group_label": "Stem cell", 
                "arm_group_type": "Experimental", 
                "description": "autologous bone marrow mononuclear cell transplantation"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "Stem cell therapy is not done for this group of spinal cord injury patients"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to study the effect of stem cell therapy on common symptoms in\n      patients with spinal cord injury."
        }, 
        "brief_title": "Stem Cell Therapy in Spinal Cord Injury", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Spinal Cord Injury", 
        "condition_browse": {
            "mesh_term": [
                "Spinal Cord Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "Autologous bone marrow mononuclear cells are administered intrathecally by a standard\n      procedure followed by vigorous rehabilitation therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed cases of any type of spinal cord injury\n\n          -  age above 12 months.\n\n        Exclusion Criteria:\n\n          -  presence of acute infections such as Human immunodeficiency virus/Hepatitis B\n             Virus/Hepatitis C Virus\n\n          -  malignancies\n\n          -  bleeding tendencies\n\n          -  pneumonia\n\n          -  renal failure\n\n          -  severe liver dysfunction\n\n          -  severe anemia [Hemoglobin < 8]\n\n          -  any bone marrow disorder\n\n          -  space occupying lesion in brain\n\n          -  other acute medical conditions such as respiratory infection and pyrexia."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "12 Months"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02009124", 
            "org_study_id": "NGBSI-03"
        }, 
        "intervention": {
            "arm_group_label": "Stem cell", 
            "description": "Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure", 
            "intervention_name": "Autologous bone marrow mononuclear cell transplantation", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "spinal cord injury", 
            "stem cell therapy", 
            "bone marrow", 
            "mononuclear cells", 
            "autologous"
        ], 
        "lastchanged_date": "December 6, 2013", 
        "location": {
            "contact": {
                "email": "alok276@gmail.com", 
                "last_name": "Alok k Sharma, M.S, M.Ch.", 
                "phone": "91-22-25281610"
            }, 
            "facility": {
                "address": {
                    "city": "Mumbai", 
                    "country": "India", 
                    "state": "Maharashtra", 
                    "zip": "400071"
                }, 
                "name": "Neurogen brain and spine institute"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "Open Label Study of Autologous Bone Marrow Mononuclear Cells in Spinal Cord Injury", 
        "overall_contact": {
            "email": "alok276@gmail.com", 
            "last_name": "Alok K Sharma, M.S, M.Ch", 
            "phone": "02225281610"
        }, 
        "overall_official": {
            "affiliation": "Neurogen Brain and Spine Institute", 
            "last_name": "Alok K Sharma, MS,MCh", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Indian Council of Medical Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in clinical symptoms of spinal cord injury after 6 months", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "reference": [
            {
                "PMID": "20353375", 
                "citation": "Kumar AA, Kumar SR, Narayanan R, Arul K, Baskaran M. Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: A phase I/II clinical safety and primary efficacy data. Exp Clin Transplant. 2009 Dec;7(4):241-8."
            }, 
            {
                "PMID": "17600518", 
                "citation": "Yoshihara T, Ohta M, Itokazu Y, Matsumoto N, Dezawa M, Suzuki Y, Taguchi A, Watanabe Y, Adachi Y, Ikehara S, Sugimoto H, Ide C. Neuroprotective effect of bone marrow-derived mononuclear cells promoting functional recovery from spinal cord injury. J Neurotrauma. 2007 Jun;24(6):1026-36."
            }, 
            {
                "PMID": "22507683", 
                "citation": "Sharma A, Gokulchandran N, Chopra G, Kulkarni P, Lohia M, Badhe P, Jacob VC. Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life. Cell Transplant. 2012;21 Suppl 1:S79-90. doi: 10.3727/096368912X633798."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02009124"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "It is a standard objective scale used for functional evaluation of the spinal cord injury patients. Its reliability and validity has been well established. It will be marked by a certified occupational therapy expert before the intervention and 6 months after the intervention.", 
            "measure": "Functional independence measure (FIM)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Neurogen Brain and Spine Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Neurogen Brain and Spine Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}